Skye Bioscience Inc (SKYE) Stock Price, Quote & News

Company Profile

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in Jan...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 410 0266

Website: skyebioscience.com

Address:

11250 El Camino Real, Suite 100, San Diego, United States

BIOTECH_GURU Oct. 4 at 9:12 PM

$SKYE I want to modify the original post to "in 7 months"... Otherwise I stand by this. Life changing gains coming imo. ****NFA****

0 · Reply

LiquidThetaLEAPS Oct. 4 at 3:12 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $SKYE Current Share Price: $4.75 Contracts: $SKYE March 20, 2026 $5 Calls Scale in: $2.26- $2.76 Scale out: $3.52-$4.52 Can Easily Capture: 60% ROI Blended DTE: 168 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

Multipliers Oct. 4 at 10:00 AM

$SKYE Decent volume on Friday's peak (aka foreshadowing) of $4.99! The one week chart shows the great anticipation of the upcoming Ph2a data release. I'm expecting a rise to $10 with the data not being released until late Oct - mid Nov, imo.

0 · Reply

Flosspicks30 Oct. 4 at 2:01 AM

$SKYE sentiment rolled over to bullish! Skipped neutral haha

0 · Reply

TuanNguyen7 Oct. 3 at 11:55 PM

$SKYE doing good after hours can’t wait for Monday

1 · Reply

DanishViking92 Oct. 3 at 8:19 PM

$SKYE Looks like a big cup taking shape.. could go as high as$40 short term or at least $15 should be realistic. It looks inevitable to me, seriously look at it:

2 · Reply

Multipliers Oct. 3 at 7:43 PM

$SKYE Get in before $10!

1 · Reply

leis5 Oct. 3 at 6:59 PM

$SKYE $5 today?

1 · Reply

jackedmund99 Oct. 3 at 6:49 PM

$SKYE breaking out Fox bitch just talked about Pharma buying out small caps the weight losd industry, abd notecards buying out the smaller companies

0 · Reply

ImHere4Lambos Oct. 3 at 6:44 PM

$SKYE

0 · Reply

Skye Bioscience: Promising Nimacimab Data Supports Buy Rating

Sep 19, 2025, 2:19 PM EDT - 15 days ago

Could This New Drug Be The Safer Way To Fight Obesity?

Sep 19, 2025, 7:00 AM EDT - 15 days ago

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting

Sep 10, 2025, 9:45 AM EDT - 24 days ago

Skye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 5, 2025, 1:35 PM EDT - 4 weeks ago

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

Sep 5, 2025, 1:30 AM EDT - 4 weeks ago

Skye Bioscience, Inc. (SKYE) Virtual KOL Event Transcript

Sep 4, 2025, 7:00 AM EDT - 4 weeks ago

Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

Sep 2, 2025, 7:00 AM EDT - 4 weeks ago

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

Aug 27, 2025, 7:00 AM EDT - 5 weeks ago

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

Aug 21, 2025, 7:00 AM EDT - 6 weeks ago

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

Aug 7, 2025, 8:36 PM EDT - 2 months ago

Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:01 PM EDT - 2 months ago

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

Jul 30, 2025, 7:00 AM EDT - 2 months ago

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

Jul 7, 2025, 11:59 PM EDT - 3 months ago

Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing

Jun 23, 2025, 7:00 AM EDT - 3 months ago

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

Jun 17, 2025, 7:00 AM EDT - 3 months ago

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions

May 22, 2025, 7:00 AM EDT - 4 months ago

Skye Bioscience to Participate in Upcoming Investment Conferences

May 19, 2025, 5:00 AM EDT - 4 months ago

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

May 13, 2025, 4:05 PM EDT - 5 months ago

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 13, 2025, 7:00 AM EDT - 5 months ago

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity

May 9, 2025, 7:20 PM EDT - 5 months ago

Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:01 PM EDT - 5 months ago

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity

May 7, 2025, 7:00 AM EDT - 5 months ago

Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025

Apr 29, 2025, 7:00 AM EDT - 5 months ago

Skye Bioscience to Participate in May Investment and Medical Conferences

Apr 16, 2025, 7:50 AM EDT - 6 months ago

A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value

Apr 15, 2025, 3:42 PM EDT - 6 months ago

Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models

LLY

Apr 15, 2025, 7:00 AM EDT - 6 months ago

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model

Apr 14, 2025, 7:00 AM EDT - 6 months ago

Skye Bioscience to Conduct Meetings at Piper Sandler Conference

Mar 20, 2025, 9:58 PM EDT - 7 months ago

Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript

Mar 14, 2025, 7:00 AM EDT - 7 months ago

Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025

Feb 20, 2025, 7:00 AM EST - 8 months ago

Skye Bioscience to Present at TD Cowen Health Care Conference

Feb 4, 2025, 7:00 AM EST - 8 months ago

Skye Bioscience Announces Participation in February Conferences

Feb 3, 2025, 9:20 AM EST - 8 months ago

MoneyShow's Best Investment Ideas For 2025: Part 8

DELL FNV MNKD MSTR SKE AMSC

Dec 19, 2024, 7:00 AM EST - 10 months ago

Skye Bioscience to Present at J.P. Morgan Healthcare Conference

Dec 10, 2024, 8:32 AM EST - 10 months ago

Skye Bioscience: Nimacimab Targets Safer Weight Loss, Speculative Buy

Nov 14, 2024, 7:00 AM EST - 11 months ago

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

Nov 7, 2024, 10:36 PM EST - 11 months ago

Skye Bioscience, Inc. (SKYE) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:01 PM EST - 11 months ago

Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights

Nov 1, 2024, 7:00 AM EDT - 1 year ago

Skye Bioscience to Announce Third Quarter 2024 Results

Oct 21, 2024, 7:00 AM EDT - 1 year ago

Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences

Oct 9, 2024, 1:13 PM EDT - 1 year ago

3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore

RENT SCWO

Sep 4, 2024, 11:26 AM EDT - 1 year ago

Skye: Moving Weight Loss Drugs To The Next Level

Aug 26, 2024, 7:00 AM EDT - 1 year ago

Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences

Aug 22, 2024, 7:00 AM EDT - 1 year ago

Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity

Aug 21, 2024, 10:00 AM EDT - 1 year ago

Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Aug 19, 2024, 11:00 AM EDT - 1 year ago

Investors With Losses In Skye Bioscience Inc Are Urged To Join Fraud Investigation With The Schall Law Firm

Aug 18, 2024, 11:00 AM EDT - 1 year ago

Skye Bioscience Inc Shareholders Encouraged Be A Part Of Fraud Investigation With The Schall Law Firm

Aug 17, 2024, 11:00 AM EDT - 1 year ago

Skye Bioscience Inc Investors Invited To Partake In Fraud Investigation With The Schall Law Firm

Aug 16, 2024, 11:00 AM EDT - 1 year ago

Skye Bioscience Inc Shareholders Encouraged To Join In Fraud Investigation With The Schall Law Firm

Aug 15, 2024, 11:00 AM EDT - 1 year ago

Skye Bioscience Inc Investors Encouraged To Join In Fraud Investigation With The Schall Law Firm

BIOTECH_GURU Oct. 4 at 9:12 PM

$SKYE I want to modify the original post to "in 7 months"... Otherwise I stand by this. Life changing gains coming imo. ****NFA****

0 · Reply

LiquidThetaLEAPS Oct. 4 at 3:12 PM

0 · Reply

Multipliers Oct. 4 at 10:00 AM

0 · Reply

Flosspicks30 Oct. 4 at 2:01 AM

$SKYE sentiment rolled over to bullish! Skipped neutral haha

0 · Reply

TuanNguyen7 Oct. 3 at 11:55 PM

$SKYE doing good after hours can’t wait for Monday

1 · Reply

DanishViking92 Oct. 3 at 8:19 PM

$SKYE Looks like a big cup taking shape.. could go as high as$40 short term or at least $15 should be realistic. It looks inevitable to me, seriously look at it:

2 · Reply

Multipliers Oct. 3 at 7:43 PM

$SKYE Get in before $10!

1 · Reply

leis5 Oct. 3 at 6:59 PM

$SKYE $5 today?

1 · Reply

jackedmund99 Oct. 3 at 6:49 PM

$SKYE breaking out Fox bitch just talked about Pharma buying out small caps the weight losd industry, abd notecards buying out the smaller companies

0 · Reply

ImHere4Lambos Oct. 3 at 6:44 PM

$SKYE

0 · Reply

BIOTECH_GURU Oct. 3 at 5:38 PM

$SKYE this is primed for a multi x run. Hang on to your shorts folks.

0 · Reply

Pdats02 Oct. 3 at 4:51 PM

$SKYE

0 · Reply

Ryan746 Oct. 3 at 4:34 PM

$SKYE

0 · Reply

leis5 Oct. 3 at 4:33 PM

$SKYE holy crap

0 · Reply

J_THunder77 Oct. 3 at 4:27 PM

$SKYE Revving up!

0 · Reply

Pipelinepivots Oct. 3 at 4:07 PM

$SKYE $ENGN $BEEM $BLNE most microcaps dilute GIPR doesn’t need to. With cash flow, $100M+ in assets, and no heavy debt, this company is positioned to run clean. When rates drop, real estate names with strong books explode first. GIPR .... is undervalued, overlooked, and designed to go wild once volume sticks

0 · Reply

nirahl Oct. 3 at 12:15 PM

$SKYE

2 · Reply

LudicrousReturns Oct. 3 at 6:34 AM

02 OCT Ludicrous Returns Stock Model Update Stocks to buy now (for 10/3 market open): $BEEM, $ENGN, $SKYE

0 · Reply

NoRiskNoGainEver Oct. 2 at 10:25 PM

$SKYE holy fuck!!

1 · Reply

DailyRipAllRight Oct. 2 at 4:54 PM

$IXHL cannibalizing my $SKYE and $APLD gains

0 · Reply

MissionaryTrader Oct. 2 at 4:19 PM

$SKYE feeling pretty good about all the shares I bought at $1.27

1 · Reply

LiquidThetaLEAPS Oct. 2 at 12:54 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $SKYE Current Share Price: $4.26 Contracts: $SKYE March 20, 2026 $5 Calls Scale in: $1.72- $2.10 Scale out: $2.68-$3.44 Can Easily Capture: 60% ROI Blended DTE: 170 Days | Join Elites here: https://liquidtheta.com/options

1 · Reply

Market Cap	147.19M
Revenue (ttm)	0.00
Net Income (ttm)	-26.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	665,200
Avg Vol	338,916
Day's Range	N/A - N/A
Shares Out	30.99M
Stochastic %K	85%
Beta	2.34
Analysts	Strong Sell
Price Target	$16.25